The popular diabetes drug Ozempic could be linked to a lower risk of cognitive problems, according to a new study conducted by researchers at the University of Oxford.
The study analyzed more than 100 million patient records in the United States, including over 20,000 who were taking semaglutide — commonly known as Ozempic or Wegovy.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
See Options
Already a member? Log in
Already a print subscriber? Click here to login/register your account
